Výsledky vyhledávání

Abstract P3-06-09: Real-world toxicity of pembrolizumab-based neoadjuvant regimen in patients with early triple negative breast cancer

Autor: Delphine Loirat, Emilie ARNAUD, Khaoula ALAOUI, Pauline VAFLARD, Sinen KORBI, Dalila MEZIANI, Lucie THIBAULT, Romain-Pacome DESMARIS, Jean-Guillaume FERON, Jean-Yves Pierga, Francois-Clement Bidard, Paul COTTU

Publikováno v: Cancer Research. 83:P3-06

Background Pembrolizumab (pembro, anti-PD-1 antibody) combined to chemotherapy (CT) in neoadjuvant/adjuvant setting has demonstrated its efficacy for early triple negative breast cancer (eTNBC). Pembro obtained FDA marketing authorization on July 26,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48c9b4b6a27e2ec783bb317d2994007e
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-09

Zobrazit plný text záznamu

Periodical

Investigators from Department of Medical Oncology Have Reported New Data on Brain Metastasis (Sacituzumab Govitecan In Metastatic Triple-negative Breast Cancer Patients Treated At Institut Curie Hospitals: Efficacy, Safety, and Impact of Brain...).

Publikováno v: Women's Health Weekly; 5/6/2024, p436-436, 1p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání